To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

August 14, 2018

Today's Rundown

Featured Story

Realm tanks again as second drug fails phase 2

Realm Therapeutics has reported its second midphase flop of the year. The setback threatens to wipe out Realm’s clinical-phase pipeline, leaving the immunology player with just a preclinical acne asset that features the same active ingredient as the failed programs.

Top Stories

Batycky exits Acorda to head up new biotech

Acorda Therapeutics’ chief technology officer, Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation.

Bioverativ executive Rogerio Vivaldi to helm cell therapy producer Sigilon

Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO. The change comes as Sigilon plans to move its cell-based therapeutic implants into the clinic for phase 1 trials.

[Sponsored] Rooted in Purpose: One Company’s Journey toward the First Treatment for a Rare Lung Disease

With a novel therapy under FDA review, Insmed hopes to change the treatment paradigm for patients in the U.S. suffering from a rare and debilitating lung disease.

Insilico, Juvenescence and the Buck Institute form AI-based venture to tackle metabolism and aging-related diseases

A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to extend life spans.

Bayer, Haplogen ink R&D deal for pulmonary diseases

Bayer and Evotec partner Haplogen will work to identify new treatments for pulmonary conditions including chronic obstructive pulmonary disease under a multiyear drug discovery and development collaboration.

Allergan taps Pfizer oncology veteran as CMO for some crucial pipeline help

As Allergan enters a key phase for its late-stage products, it’s bringing in a veteran executive for backup. The Dublin drugmaker has poached Charles Hugh-Jones, the chief medical officer at Pfizer Oncology, to serve as its new SVP and chief medical officer.

Resources

[Whitepaper] Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure.

[Whitepaper] HOW TO POSITION YOUR PATIENT SUPPORT PROGRAM FOR SUCCESS

When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients.

[Whitepaper] Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites

Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals.

[Survey] Industry Report: Findings from the 2018 Unified Clinical Operations Survey

Industry Research: See new results from one of the industry's largest, global clinical operations surveys.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.